968 related articles for article (PubMed ID: 29228203)
1. In vivo cholinergic basal forebrain atrophy predicts cognitive decline in de novo Parkinson's disease.
Ray NJ; Bradburn S; Murgatroyd C; Toseeb U; Mir P; Kountouriotis GK; Teipel SJ; Grothe MJ
Brain; 2018 Jan; 141(1):165-176. PubMed ID: 29228203
[TBL] [Abstract][Full Text] [Related]
2. Structural and molecular cholinergic imaging markers of cognitive decline in Parkinson's disease.
Schumacher J; Kanel P; Dyrba M; Storch A; Bohnen NI; Teipel S; Grothe MJ
Brain; 2023 Dec; 146(12):4964-4973. PubMed ID: 37403733
[TBL] [Abstract][Full Text] [Related]
3. Cholinergic Basal Forebrain Volumes Predict Gait Decline in Parkinson's Disease.
Wilson J; Yarnall AJ; Craig CE; Galna B; Lord S; Morris R; Lawson RA; Alcock L; Duncan GW; Khoo TK; O'Brien JT; Burn DJ; Taylor JP; Ray NJ; Rochester L
Mov Disord; 2021 Mar; 36(3):611-621. PubMed ID: 33382126
[TBL] [Abstract][Full Text] [Related]
4. Longitudinal degeneration of the basal forebrain predicts subsequent dementia in Parkinson's disease.
Pereira JB; Hall S; Jalakas M; Grothe MJ; Strandberg O; Stomrud E; Westman E; van Westen D; Hansson O
Neurobiol Dis; 2020 Jun; 139():104831. PubMed ID: 32145376
[TBL] [Abstract][Full Text] [Related]
5. Free-water imaging of the cholinergic basal forebrain and pedunculopontine nucleus in Parkinson's disease.
Ray NJ; Lawson RA; Martin SL; Sigurdsson HP; Wilson J; Galna B; Lord S; Alcock L; Duncan GW; Khoo TK; O'Brien JT; Burn DJ; Taylor JP; Rea RC; Bergamino M; Rochester L; Yarnall AJ
Brain; 2023 Mar; 146(3):1053-1064. PubMed ID: 35485491
[TBL] [Abstract][Full Text] [Related]
6. Nucleus basalis of Meynert degeneration precedes and predicts cognitive impairment in Parkinson's disease.
Schulz J; Pagano G; Fernández Bonfante JA; Wilson H; Politis M
Brain; 2018 May; 141(5):1501-1516. PubMed ID: 29701787
[TBL] [Abstract][Full Text] [Related]
7. Basal Forebrain Atrophy, Cortical Thinning, and Amyloid-β Status in Parkinson's disease-Related Cognitive Decline.
Labrador-Espinosa MA; Silva-Rodríguez J; Reina-Castillo MI; Mir P; Grothe MJ
Mov Disord; 2023 Oct; 38(10):1871-1880. PubMed ID: 37492892
[TBL] [Abstract][Full Text] [Related]
8. Cholinergic basal forebrain and hippocampal structure influence visuospatial memory in Parkinson's disease.
Berlot R; Pirtošek Z; Brezovar S; Koritnik B; Teipel SJ; Grothe MJ; Ray NJ
Brain Imaging Behav; 2022 Feb; 16(1):118-129. PubMed ID: 34176042
[TBL] [Abstract][Full Text] [Related]
9. Atrophy of the Cholinergic Basal Forebrain can Detect Presynaptic Cholinergic Loss in Parkinson's Disease.
Ray NJ; Kanel P; Bohnen NI
Ann Neurol; 2023 May; 93(5):991-998. PubMed ID: 36597786
[TBL] [Abstract][Full Text] [Related]
10. Basal forebrain integrity, cholinergic innervation and cognition in idiopathic Parkinson's disease.
Crowley SJ; Kanel P; Roytman S; Bohnen NI; Hampstead BM
Brain; 2024 May; 147(5):1799-1808. PubMed ID: 38109781
[TBL] [Abstract][Full Text] [Related]
11. Quantitative EEG and cholinergic basal forebrain atrophy in Parkinson's disease and mild cognitive impairment.
Rea RC; Berlot R; Martin SL; Craig CE; Holmes PS; Wright DJ; Bon J; Pirtošek Z; Ray NJ
Neurobiol Aging; 2021 Oct; 106():37-44. PubMed ID: 34233212
[TBL] [Abstract][Full Text] [Related]
12. Increased basal forebrain volumes could prevent cognitive decline in LRRK2 Parkinson's disease.
Batzu L; Urso D; Grothe MJ; Veréb D; Chaudhuri KR; Pereira JB
Neurobiol Dis; 2023 Jul; 183():106182. PubMed ID: 37286171
[TBL] [Abstract][Full Text] [Related]
13. In vivo cholinergic basal forebrain degeneration and cognition in Parkinson's disease: Imaging results from the COPPADIS study.
Grothe MJ; Labrador-Espinosa MA; Jesús S; Macías-García D; Adarmes-Gómez A; Carrillo F; Camacho EI; Franco-Rosado P; Lora FR; Martín-Rodríguez JF; Barberá MA; Pastor P; Arroyo SE; Vila BS; Foraster AC; Martínez JR; Padilla FC; Morlans MP; Aramburu IG; Ceberio JI; Vara JH; de Fábregues-Boixar O; de Deus Fonticoba T; Pascual-Sedano B; ; Kulisevsky J; Martínez-Martín P; Santos-García D; Mir P
Parkinsonism Relat Disord; 2021 Jul; 88():68-75. PubMed ID: 34144230
[TBL] [Abstract][Full Text] [Related]
14. Olfaction, cholinergic basal forebrain degeneration, and cognition in early Parkinson disease.
Barrett MJ; Murphy JM; Zhang J; Blair JC; Flanigan JL; Nawaz H; Dalrymple WA; Sperling SA; Patrie J; Druzgal TJ
Parkinsonism Relat Disord; 2021 Sep; 90():27-32. PubMed ID: 34348192
[TBL] [Abstract][Full Text] [Related]
15. Early nucleus basalis of Meynert degeneration predicts cognitive decline in Parkinson's disease.
Gratwicke JP; Foltynie T
Brain; 2018 Jan; 141(1):7-10. PubMed ID: 29325047
[No Abstract] [Full Text] [Related]
16. Clinical and Cerebral Metabolic Changes in Parkinson's Disease With Basal Forebrain Atrophy.
Gang M; Baba T; Hosokai Y; Nishio Y; Kikuchi A; Hirayama K; Hasegawa T; Aoki M; Takeda A; Mori E; Suzuki K
Mov Disord; 2020 May; 35(5):825-832. PubMed ID: 31971293
[TBL] [Abstract][Full Text] [Related]
17. Subregional volume reduction of the cholinergic forebrain in subjective cognitive decline (SCD).
Scheef L; Grothe MJ; Koppara A; Daamen M; Boecker H; Biersack H; Schild HH; Wagner M; Teipel S; Jessen F
Neuroimage Clin; 2019; 21():101612. PubMed ID: 30555006
[TBL] [Abstract][Full Text] [Related]
18. The cholinergic system in mild cognitive impairment and Alzheimer's disease: an in vivo MRI and DTI study.
Teipel SJ; Meindl T; Grinberg L; Grothe M; Cantero JL; Reiser MF; Möller HJ; Heinsen H; Hampel H
Hum Brain Mapp; 2011 Sep; 32(9):1349-62. PubMed ID: 20672311
[TBL] [Abstract][Full Text] [Related]
19. The basal forebrain cholinergic system as target for cell replacement therapy in Parkinson's disease.
Björklund A; Barker RA
Brain; 2024 Jun; 147(6):1937-1952. PubMed ID: 38279949
[TBL] [Abstract][Full Text] [Related]
20. Clinical variables and biomarkers in prediction of cognitive impairment in patients with newly diagnosed Parkinson's disease: a cohort study.
Schrag A; Siddiqui UF; Anastasiou Z; Weintraub D; Schott JM
Lancet Neurol; 2017 Jan; 16(1):66-75. PubMed ID: 27866858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
